Edgar Filing: Altus Pharmaceuticals Inc. - Form 4

Altus Pharm Form 4 October 01,	aceuticals Inc. 2007										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB Number:	PROVAL 3235-0287 January 31,	
if no long subject to Section 1 Form 4 c Form 5		GES IN SECUR	Expires: 2005 Estimated average burden hours per response 0.5								
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type]	Responses)										
1. Name and Address of Reporting Person <u>*</u> Gallotto Robert			2. Issuer Name and Ticker or Trading Symbol Altus Pharmaceuticals Inc. [ALTU]					5. Relationship of Reporting Person(s) to Issuer			
(Last) C/O ALTU PHARMAC SIDNEY S	3. Date of Earliest Transaction (Month/Day/Year) 10/01/2007					(Check all applicable) <u> </u>					
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person					
CAMBRID	GE, MA 02139)						Form filed by N Person	Iore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Executio any		3. Transactic Code (Instr. 8)		ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Common	10/01/2007			Code V		(D)	Price	(Instr. 3 and 4)	D		
Stock	10/01/2007			М	500	A	\$ 3.92	500	D		
Common Stock	10/01/2007			S <u>(1)</u>	500	D	\$ 10.56	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Altus Pharmaceuticals Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number on of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities8(Instr. 3 and 4)5(Instr. 3 and 4)6	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 3.92	10/01/2007		М	500	12/20/2002 <u>(2)</u>	12/19/2012	Common Stock	500

Reporting Owners

Reporting Owner Name / Address	Relationships					
1. 9	Director	10% Owner	Officer	Other		
Gallotto Robert C/O ALTUS PHARMACEUTICALS INC. 125 SIDNEY STREET CAMBRIDGE, MA 02139			VP, Strategic Planning			
Signatures						

/s/ Robert Gallotto 10/01/2007 Date **Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Gallotto on September 1, 2006.

(2) All of such options have a term of ten years vesting over four years, with 1/16 of the options vesting every three months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.